Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Leases: 2019-2024

Historic Current Leases for Intellia Therapeutics (NTLA) over the last 6 years, with Dec 2024 value amounting to $20.2 million.

  • Intellia Therapeutics' Current Leases rose 42.76% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 42.76%. This contributed to the annual value of $20.2 million for FY2024, which is 8.86% up from last year.
  • As of FY2024, Intellia Therapeutics' Current Leases stood at $20.2 million, which was up 8.86% from $18.6 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Current Leases registered a high of $20.2 million during FY2024, and its lowest value of $5.7 million during FY2020.
  • In the last 3 years, Intellia Therapeutics' Current Leases had a median value of $18.6 million in 2023 and averaged $18.5 million.
  • Its Current Leases has fluctuated over the past 5 years, first dropped by 0.85% in 2020, then spiked by 83.11% in 2022.
  • Intellia Therapeutics' Current Leases (Yearly) stood at $5.7 million in 2020, then skyrocketed by 59.97% to $9.1 million in 2021, then skyrocketed by 83.11% to $16.7 million in 2022, then grew by 11.47% to $18.6 million in 2023, then increased by 8.86% to $20.2 million in 2024.